Medifocus Inc V.MFS

Primary Symbol: MDFZF

Healthcare Biotechnology

Medifocus Inc develops and sells minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostate Hyperplasia (BHP). It owns two focused heat technology platforms, The Endo-thermotherapy Platform-from which Prolieve was developed, can be used to treat cancers in prostate, rectal, cervical and esophageal, and The Adaptive Phased Array Microwave Focusing Platform which directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The company through its operations generates revenue from the United States.

EXPM:MDFZF - Post by User

Medifocus Inc

Bullboard Posts

Post by Bullboards_Sealon Sep 09, 2014 1:51pm

201 Views

Post# 22920086

NR - Medifocus Announces Retraction of Prior Press Release..

COLUMBIA, MARYLAND and TORONTO, ONTARIO--(Marketwired - Sept. 8, 2014) - Medifocus Inc. (TSX VENTURE:MFS)(OTCQX:MDFZF) (Medifocus) issued a press release earlier today regarding the initiation of research coverage by SeeThruEquity that inadvertently included a target price from the research report. Medifocus hereby retracts this press release.

About Medifocus, Inc.

Medifocus owns two fully developed technology platforms with comprehensive United States and international patent protection: (i) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The United States Food and Drug Administration (FDA) approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. Medifocus' APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, has received approval from the FDA and Health Canada to conduct the pivotal Phase III clinical trials. Medifocus believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers. Please visit www.medifocusinc.com, www.prolieve.com and https://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Medifocus Inc.
John Mon
COO
410-290-5734
JohnMon@medifocusinc.com

Read more at https://www.stockhouse.com/news/press-releases/2014/09/08/medifocus-announces-retraction-of-prior-press-release#HlvmRpEwd8gAjYWA.99

Bullboard Posts

Who, why, and what of the great "Crypto Surge"